A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Completed · Phase 3 · NCT05931380
Conditions: Obesity
At a glance
- Research payments reported, 2025
- $132
- U.S. investigators named
- 3
- Sites paid
- 1
- Planned or actual enrollment
- 238
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2023-07-31; completion 2025-06-19
- Results posted
- Yes
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
From ClinicalTrials.gov, last updated 2026-07-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $132 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anirudh R. Nandan Student in an Organized Health Care Education/Training Program · San Francisco, CA
- Alejandro Duran Crane, MD Internal Medicine · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.